Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30974 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Ramya Ramakrishnan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Hematology Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Down Syndrome, Cytarabine, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Pediatric Hematology Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Hematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Johann Hitzler
Zitieren
APA
Ramakrishnan, R., Munir, F., Quesada, A. E., Hitzler, J., & Cuglievan, B. (2024). Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30974
Vancouver
Ramakrishnan R, Munir F, Quesada AE, Hitzler J, Cuglievan B. Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30974
BibTeX
@article{Ramakrishnan2024,
author = {Ramakrishnan, Ramya and Munir, Faryal and Quesada, Andres Ernesto and Hitzler, Johann and Cuglievan, Branko},
title = {Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30974}
}
EUVIMED